Use of cookies by
Norton Rose Fulbright
We use cookies to deliver our online services. Details and instructions on how to disable those cookies are set out at nortonrosefulbright.com/cookies-policy. By continuing to use this website you agree to our use of our cookies unless you have disabled them.
Norton Rose Fulbright advises on largest UK IPO this year | Global law firm | Norton Rose Fulbright

Norton Rose Fulbright advises on largest UK IPO this year

March 30, 2017

Contacts

Global law firm Norton rose Fulbright has advised Goldman Sachs International and J.P. Morgan Cazenove, as global co-ordinators and bookrunners, on the IPO of BioPharma Credit PLC, a new UK investment trust which will be managed by Pharmakon Advisers, L.P., a New York based manager specialising in biopharma royalty investing and lending. This IPO is the largest in the UK this year.

BioPharma’s investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The IPO involved an institutional placing and offer for subscription. In addition, BioPharma has acquired a portfolio of seed assets through the implementation of several tender offers made to investors in existing funds managed by Pharmakon and its affiliates. The shares issued pursuant to the IPO have been admitted to trading on the Specialist Fund Segment of the Main Market of the London Stock Exchange and to listing and trading on the Official List of the Channel Islands Stock Exchange.

The team was led by Ian Fox, assisted by associate Abhimanyu George Jain. Tom Vita led in relation to US securities aspects assisted by Kevin Connolly. 

Ian Fox, partner in the London office commented:

“This was an extremely complex deal which we are delighted to have advised upon. Exceeding the original target of $300m illustrates the attractiveness of the investment in today’s current market.”

For further information please contact:

Kate Farrell, PR Assistant
Tel: +44 (0)20 7444 3724; Mob: +44 (0) 7515 324 290
kate.farrell@nortonrosefulbright.com

Notes for editors:

Norton Rose Fulbright is a global law firm. We provide the world’s preeminent corporations and financial institutions with a full business law service. We have more than 3500 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright Verein, a Swiss verein, helps coordinate the activities of Norton Rose Fulbright members but does not itself provide legal services to clients. Norton Rose Fulbright has offices in more than 50 cities worldwide, including London, Houston, Toronto, Sydney and Johannesburg. For more information, see nortonrosefulbright.com/legal-notices.